Lakefront Biotherapeutics (LKFT) Equity Ratio (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has 12 years of Equity Ratio data on file, last reported at 0.95 in Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.95, up 35.61% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.95 (up 35.61% YoY), and the FY2025 annual result was 0.95, up 35.61% from the prior year.
• Equity Ratio advanced to 0.95 in Q4 2025 per LKFT's latest filing, from 0.7 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.95 in Q4 2025 and troughed at 0.51 in Q4 2021.
• A 5-year average of 0.67 and a median of 0.64 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio advanced 4.82% in 2022, then surged 35.61% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.51 in 2021, then advanced by 4.82% to 0.53 in 2022, then grew by 20.24% to 0.64 in 2023, then climbed by 9.18% to 0.7 in 2024, then jumped by 35.61% to 0.95 in 2025.
• Business Quant data shows LKFT's Equity Ratio at 0.95 in Q4 2025, 0.7 in Q4 2024, and 0.64 in Q4 2023.